Skip to main content
Smart Investors Daily
CT

NASDAQ · CTKB

Cytek Biosciences, Inc.

Healthcare · Medical - Devices

$6.14

Up+$0.16 (+2.68%)

Updated Oct 29, 2026, 5:23 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
636.75M
P/E ratio
-98.76
Dividend yield
0.00%
52-week range
$3.31 – $6.21
Volume
1.6M
Avg. volume
1.17M

Price performance · CTKB

CTKB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 28, 2026

CTKB closed at $6.14 after 21 trading sessions, up 3.02% for the selected period.

Last close
$6.14
Period change
+3.02%
Period low
$5.25
Period high
$6.14
Daily close
View OHLC price history
CTKB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 28, 2026$5.95$6.32$5.95$6.141.6M
Oct 27, 2026$5.89$6.01$5.795$5.981.21M
Oct 26, 2026$5.60$5.895$5.59$5.891.24M
Oct 23, 2026$5.38$5.64$5.30$5.59704.86K
Oct 22, 2026$5.53$5.66$5.35$5.43694.3K
Oct 21, 2026$5.26$5.545$5.24$5.501.09M
Oct 20, 2026$5.29$5.49$5.26$5.34805.96K
Oct 19, 2026$5.27$5.34$5.19$5.25700.55K
Oct 16, 2026$5.41$5.41$5.205$5.251.05M
Oct 15, 2026$5.36$5.48$5.29$5.41905.4K
Oct 14, 2026$5.25$5.475$5.23$5.3951.07M
Oct 13, 2026$5.19$5.465$5.18$5.351.43M
Oct 12, 2026$5.42$5.42$5.115$5.311.04M
Oct 9, 2026$5.32$5.555$5.30$5.433.88M
Oct 8, 2026$5.26$5.38$5.045$5.361.71M
Oct 7, 2026$5.21$5.34$5.1101$5.341.78M
Oct 6, 2026$6.13$6.21$5.355$5.382.05M
Oct 5, 2026$5.88$6.105$5.825$6.091.79M
Oct 2, 2026$5.86$5.94$5.75$5.871.1M
Oct 1, 2026$5.96$5.97$5.7501$5.811.57M
Sep 30, 2026$5.76$5.985$5.67$5.961.32M

Latest CTKB news

The latest Smart Investors Daily articles mentioning CTKB.

CTKB research

Overview

Company profile and research snapshot.

Company profile

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
CTKB recent ratings
DateFirmRatingTarget
May 13, 2026Stephens & Co.Overweight—
May 12, 2026Morgan StanleyEqual-Weight—
Jan 8, 2026TD CowenBuy—
Nov 11, 2025Piper SandlerOverweight—
May 28, 2025Morgan StanleyEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 25, 2026

Cytek Biosciences (CTKB) Stock Sees Modest Fair Value Lift As Analysts Weigh Profitability

Cytek Biosciences is back in focus as fair value estimates have shifted from about US$5.69 to roughly US$6.17 per share, reflecting a modest reset in price targets. Analysts cluster around this updated range with a mix of optimism and caution, linking their views to how the company executes on profitability and what feels reasonable for future P/E levels. As you read on, you will see how these moving targets shape the evolving Cytek Biosciences story and what to watch next. Analyst Price...

Yahoo · Oct 21, 2026

Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The company’s management will also host a conference call to discuss its results, business developments and outlook beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. A live audio webcast of the call will be availa

Yahoo · Sep 29, 2026

Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability

Brown Capital Management, an investment management company, released its second-quarter 2026 investor letter for “The Brown Capital Management Small Company Fund.” The letter can be downloaded here. For the quarter ended June 30, 2026, market volatility reflected uncertainty around AI spending and Middle East tensions. The Magnificent Seven fell more than 8% in June, while […]

Yahoo · Sep 23, 2026

Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool

Industry’s First End-to-End Flow Cytometry Platform Covering Panel Design Through Data Analysis Cytek® Cloud digital ecosystem Cytek® Biosciences has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool, establishing the industry’s first end-to-end platform that integrates the entire flow cytometry workflow, from panel design to data analysis, into one system. FREMONT, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.